The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study

Objective The aim of this study was to assess the correlation between serum and intestinal anti-tumour necrosis factor (TNF) levels, and their relationship to endoscopic disease activity and levels of TNF. Design Cross-sectional study of 30 patients receiving treatment with infliximab or adalimumab for Crohn's disease or UC. For each patient, a sample of serum was matched to tissue biopsies. Endoscopic and histological disease activity was recorded for each tissue sample. Results There was a significant positive correlation between anti-TNF in serum and tissue (r=0.3920, p=0.002), especially in uninflamed tissue (r=0.50, p<0.001), but not with those samples that had inflammation (r=0.19, p=0.54). Anti-TNF concentration in tissue correlated with degree of endoscopic inflammation, except for tissue with severe inflammation in which anti-TNF levels were again lower (mean normalised anti-TNF in tissue: uninflamed=0.93, mild=2.17, moderate=13.71, severe=2.2 inflammation (p=0.0042)). The ratio of anti-TNF-to-TNF in tissue was highest in uninflamed areas and lowest in severely inflamed areas. Patients with active mucosal disease had a higher rate of serum to tissue drug level mismatch when compared to those in remission (73.3% vs 33.3%, respectively; p=0.03). Conclusions Our data suggest that local tissue inflammation characterised by high levels of TNF serves as a sink for anti-TNF. We further postulate that some patients with high serum anti-TNF levels have active disease because tissue levels of anti-TNF are insufficient to neutralise local TNF production.

[1]  G. Greenberg,et al.  A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease , 2014, Alimentary pharmacology & therapeutics.

[2]  Wolfgang Uter,et al.  In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease , 2014, Nature Medicine.

[3]  Hui Zhang,et al.  Epithelium percentage estimation facilitates epithelial quantitative protein measurement in tissue specimens , 2013, Clinical Proteomics.

[4]  C. Ponsioen,et al.  157 Fecal Loss of Infliximab As a Cause of Lack of Response in Severe Inflammatory Bowel Disease , 2013 .

[5]  S. Vermeire,et al.  Serum Adalimumab Concentration and Clinical Remission in Patients with Crohn's Disease , 2013, Inflammatory bowel diseases.

[6]  Joon-Oh Park,et al.  A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers , 2013, PloS one.

[7]  Sharat Singh,et al.  Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. , 2012, Journal of immunological methods.

[8]  S. Ng,et al.  Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients , 2011, Proteome Science.

[9]  S. Schreiber,et al.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial , 2011, Gut.

[10]  W. Sandborn,et al.  Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[11]  V. Loening-Baucke,et al.  Mucosal flora in Crohn's disease and ulcerative colitis - an overview. , 2009, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[12]  G. Cui,et al.  TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. , 2009, Cytokine.

[13]  A. Gorąca,et al.  Effect of alpha-lipoic acid on LPS-induced oxidative stress in the heart. , 2009, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[14]  G. D'Haens,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial , 2008 .

[15]  S. Hanauer,et al.  Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial , 2007, Gut.

[16]  B. Vonen,et al.  Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis , 2007, Scandinavian journal of gastroenterology.

[17]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[18]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[19]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[20]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[21]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[22]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[23]  T. Toyota,et al.  Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease , 1998, Gut.

[24]  R. Coffman,et al.  Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. , 1994, Immunity.

[25]  T. Macdonald,et al.  Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease , 1994 .

[26]  T. Macdonald,et al.  Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. , 1994, Gastroenterology.

[27]  T. Macdonald,et al.  Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. , 1993, Gut.

[28]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.